Metastatic breast cancer response after Exemestane withdrawal: A case report

Breast

Volumn 13, Issue 1, 2004, Pages 66-68

  Bhide, S A ^a   Rea, D W ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Breast cancer; Exemestane; Metastatic; Response; Withdrawal

Indexed keywords

ANASTROZOLE; DOXORUBICIN; EXEMESTANE; IDOXIFENE; TAMOXIFEN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CLINICAL TRIAL; DISEASE COURSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MASTECTOMY; MEDICAL DOCUMENTATION; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 1242342972     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2003.09.009     Document Type: Article

References (5)

1. Vasily J, Budzar A, et al. Recent advances in aromatase inhibitor therapy for breast cancer. Semin Oncol 2002;29(suppl 11):120-8.
2. Legault-Poisson S, Jolivet J, Poisson R, et al. Tamoxifen-induced tumour stimulation and withdrawal response. Cancer Treatment Rep 1979;63:1839-41.
3. Stein III W, Hortobagyi GN, Blumenschein GR. Response of metastatic breast cancer to Tamoxifen withdrawal: report of a case. J Surg Oncol 1983;22:45-6.
4. Dirix LY, Piccart M, Lohrisch C, et al. Efficacy and tolerance to Exemestane (E) versus Tamoxifen (T) in first line hormonal therapy (HT) of postmenopausal patients (pts) with metastatic breast cancer (MBC): A European Organisation for the Research and Treatment of Cancer Randomised Phase II Trial (EORTC 109510). Proceedings of the ASCO, 2001, Abstract 114.
5. Song X-D, Mor G, Naftolin F, et al. Effect of long term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-Estradiol. J Natl Cancer Inst 2001;93: 1714-23.